Multiple Myeloma | Specialty

Weekly Carfilzomib Safe and Effective in Relapsed or Refractory Multiple Myeloma

August 15th 2014

Administering carfilzomib once weekly in combination with dexamethasone is safe, with few ≥3 adverse events, and has significant antitumor activity in the treatment of patients with relapsed or refractory multiple myeloma.

Carfilzomib Monotherapy Misses Survival Endpoint in Heavily Pretreated Myeloma

August 14th 2014

Treatment with single-agent carfilzomib (Kyprolis) was unable to significantly extend overall survival (OS) compared with best supportive care in heavily pretreated patients with multiple myeloma

Daratumumab Active in Relapsed/Refractory Multiple Myeloma

August 14th 2014

Daratumumab, a fully human IgG1k monoclonal antibody that targets CD38, has demonstrated promising activity as monotherapy in patients with relapsed/refractory multiple myeloma

FDA Expands Bortezomib Multiple Myeloma Label

August 11th 2014

The FDA has expanded the bortezomib (Velcade) label to allow for retreatment in patients with multiple myeloma who previously responded to the proteasome inhibitor, according to an announcement made by Millennium/Takeda, the companies that manufacture the drug.

Carfilzomib Combination Effective for Relapsed Myeloma

August 4th 2014

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma

Emerging Agents for Multiple Myeloma

July 10th 2014

Management of Adverse Events in Multiple Myeloma

July 10th 2014

Maintenance Therapy for Patients With Multiple Myeloma

July 10th 2014

Pomalidomide and Carfilzomib in Multiple Myeloma

July 10th 2014

Pomalidomide in Refractory Multiple Myeloma

July 10th 2014

Treatment Decisions in Relapsed/Refractory Myeloma

July 10th 2014

Treatment Options in Newly Diagnosed Multiple Myeloma

July 10th 2014

High-Risk and Smoldering Multiple Myeloma

July 10th 2014

Imaging and Treatment Advances in Multiple Myeloma

July 10th 2014

Novel Epigenetic Therapy Shows Clinical Activity in Hematologic Malignancies

July 2nd 2014

Preliminary evidence supports the use of bromodomain inhibitors in hematologic malignancies, including acute leukemia (mainly acute myelogenous leukemia) and other hematological malignancies, including diffuse large B-cell lymphoma and multiple myeloma.

Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial

June 17th 2014

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Dr. Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in Myeloma

June 6th 2014

Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses excitement over the development of CD38-targeted monoclonal antibodies as treatments for patients with multiple myeloma.

Dr. Berenson Discusses Results from the CHAMPION-1 Trial

June 6th 2014

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Panobinostat Combination Improves PFS in Multiple Myeloma

June 3rd 2014

Combining panobinostat (LBH589) with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.